Log in

NASDAQ:STSA - Satsuma Pharmaceuticals Stock Price, Forecast & News

-0.25 (-0.95 %)
(As of 02/26/2020 09:17 AM ET)
Today's Range
Now: $26.10
50-Day Range
MA: $23.80
52-Week Range
Now: $26.10
Volume54,081 shs
Average Volume51,416 shs
Market Capitalization$453.62 million
P/E RatioN/A
Dividend YieldN/A
Satsuma Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops a novel therapeutic product for the acute treatment of migraine. Its product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in Phase III clinical trials and can be self-administered with a proprietary pre-filled single-use nasal delivery device. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryRegional Banks
Current SymbolNASDAQ:STSA



Sales & Book Value

Annual SalesN/A



Market Cap$453.62 million
Next Earnings DateN/A
OptionableNot Optionable

Receive STSA News and Ratings via Email

Sign-up to receive the latest news and ratings for STSA and its competitors with MarketBeat's FREE daily newsletter.

Satsuma Pharmaceuticals (NASDAQ:STSA) Frequently Asked Questions

What is Satsuma Pharmaceuticals' stock symbol?

Satsuma Pharmaceuticals trades on the NASDAQ under the ticker symbol "STSA."

How were Satsuma Pharmaceuticals' earnings last quarter?

Satsuma Pharmaceuticals (NASDAQ:STSA) posted its quarterly earnings results on Tuesday, November, 12th. The financial services provider reported ($2.26) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.01) by $1.25. View Satsuma Pharmaceuticals' Earnings History.

What price target have analysts set for STSA?

4 brokerages have issued 1 year price objectives for Satsuma Pharmaceuticals' stock. Their forecasts range from $16.00 to $20.00. On average, they anticipate Satsuma Pharmaceuticals' stock price to reach $18.00 in the next twelve months. This suggests that the stock has a possible downside of 31.0%. View Analyst Price Targets for Satsuma Pharmaceuticals.

What is the consensus analysts' recommendation for Satsuma Pharmaceuticals?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Satsuma Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Satsuma Pharmaceuticals.

Has Satsuma Pharmaceuticals been receiving favorable news coverage?

Press coverage about STSA stock has trended somewhat negative recently, InfoTrie Sentiment Analysis reports. InfoTrie rates the sentiment of press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Satsuma Pharmaceuticals earned a news sentiment score of -1.0 on InfoTrie's scale. They also assigned media coverage about the financial services provider a news buzz of 5.0 out of 10, meaning that recent press coverage is somewhat likely to have an impact on the company's share price in the next few days. View News Stories for Satsuma Pharmaceuticals.

Are investors shorting Satsuma Pharmaceuticals?

Satsuma Pharmaceuticals saw a drop in short interest during the month of January. As of January 31st, there was short interest totalling 141,500 shares, a drop of 18.3% from the January 15th total of 173,300 shares. Based on an average trading volume of 76,700 shares, the days-to-cover ratio is presently 1.8 days. Approximately 1.1% of the shares of the stock are sold short. View Satsuma Pharmaceuticals' Current Options Chain.

Who are some of Satsuma Pharmaceuticals' key competitors?

What other stocks do shareholders of Satsuma Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Satsuma Pharmaceuticals investors own include AbbVie (ABBV), Gilead Sciences (GILD), Carnival (CCL), Canadian Natural Resources (CNQ), Enterprise Products Partners (EPD), Suncor Energy (SU), Adobe (ADBE), Huntington Bancshares (HBAN), Intel (INTC) and Karuna Therapeutics (KRTX).

Who are Satsuma Pharmaceuticals' key executives?

Satsuma Pharmaceuticals' management team includes the folowing people:
  • Mr. John A. Kollins, Pres, CEO & Director (Age 56)
  • Dr. Detlef F. Albrecht, Chief Medical Officer (Age 58)
  • Mr. Thomas P. O'Neil, Chief Financial Officer (Age 54)
  • Mr. Mic Iwashima, VP & Head of Operations (Age 41)
  • Mr. Robert Schultz, VP & Head of CMC (Age 55)

When did Satsuma Pharmaceuticals IPO?

(STSA) raised $75 million in an initial public offering (IPO) on Friday, September 13th 2019. The company issued 5,000,000 shares at $14.00-$16.00 per share. Credit Suisse, SVB Leerink and Evercore acted as the underwriters for the IPO.

When does Satsuma Pharmaceuticals' lock-up period expire?

Satsuma Pharmaceuticals' lock-up period expires on Wednesday, March 11th. Satsuma Pharmaceuticals had issued 5,500,000 shares in its IPO on September 13th. The total size of the offering was $82,500,000 based on an initial share price of $15.00. Shares of the company owned by major shareholders and company insiders will be eligible for trade following the end of the lock-up period.

Who are Satsuma Pharmaceuticals' major shareholders?

Satsuma Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Geode Capital Management LLC (0.37%), Credit Suisse AG (0.31%), State Street Corp (0.24%), Charles Schwab Investment Management Inc. (0.19%), Janus Henderson Group PLC (0.08%) and UBS Group AG (0.03%). Company insiders that own Satsuma Pharmaceuticals stock include Group Holdings (Sbs) Advis Tpg, Louis F Centofanti and Rajeev M Shah. View Institutional Ownership Trends for Satsuma Pharmaceuticals.

Which major investors are selling Satsuma Pharmaceuticals stock?

STSA stock was sold by a variety of institutional investors in the last quarter, including Credit Suisse AG. View Insider Buying and Selling for Satsuma Pharmaceuticals.

Which major investors are buying Satsuma Pharmaceuticals stock?

STSA stock was purchased by a variety of institutional investors in the last quarter, including Geode Capital Management LLC, State Street Corp, Charles Schwab Investment Management Inc., Janus Henderson Group PLC, New York State Common Retirement Fund, UBS Group AG, American International Group Inc. and Victory Capital Management Inc.. Company insiders that have bought Satsuma Pharmaceuticals stock in the last two years include Group Holdings (Sbs) Advis Tpg, Louis F Centofanti and Rajeev M Shah. View Insider Buying and Selling for Satsuma Pharmaceuticals.

How do I buy shares of Satsuma Pharmaceuticals?

Shares of STSA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Satsuma Pharmaceuticals' stock price today?

One share of STSA stock can currently be purchased for approximately $26.10.

How big of a company is Satsuma Pharmaceuticals?

Satsuma Pharmaceuticals has a market capitalization of $453.62 million. Satsuma Pharmaceuticals employs 11 workers across the globe.View Additional Information About Satsuma Pharmaceuticals.

What is Satsuma Pharmaceuticals' official website?

The official website for Satsuma Pharmaceuticals is http://www.satsumarx.com/.

How can I contact Satsuma Pharmaceuticals?

Satsuma Pharmaceuticals' mailing address is 400 OYSTER POINT BOULEVARD SUITE 221, SOUTH SAN FRANCISCO CA, 64080. The financial services provider can be reached via phone at 650-410-3200.

MarketBeat Community Rating for Satsuma Pharmaceuticals (NASDAQ STSA)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  191 (Vote Outperform)
Underperform Votes:  211 (Vote Underperform)
Total Votes:  402
MarketBeat's community ratings are surveys of what our community members think about Satsuma Pharmaceuticals and other stocks. Vote "Outperform" if you believe STSA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe STSA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/26/2020 by MarketBeat.com Staff

Featured Article: What Are Cryptocurrencies?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel